Editas Medicine, Inc. $90 Million Follow-On Offering
3/22/2017

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $90 million follow-on offering of 4,000,000 shares of common stock of Editas Medicine, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “EDIT.”

Based in Cambridge, Massachusetts, Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes.  The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Marcel Fausten and associates Cameron C. Lewis and Paul Lee. The intellectual property and technology team included counsel David R. Bauer and associate Bonnie Chen. Counsel Marcie A. Goldstein provided FINRA advice. The tax team included partner Po Sit and associate K. Daniel Berman. All members of the Davis Polk team are based in the New York office.